Giuliani S.p.A acquires majority stake in MIKA Pharma GmbH
MIKA Pharma GmbH announced that Giuliani S.p.A, a Milano, Italy based Pharma company has acquired a majority stake in MIKA Pharma.
Based on its proprietary nanoemulsion drug delivery technology, MIKA Pharma has developed a wide range of topical products including Diclofenac Spray, Ketoprofen Spray, and Heparin Spray. All of these products were successfully developed by MIKA Pharma and are currently registered in 32 countries. MIKA Pharma has granted licensing rights to a variety of partners to commercialise these products. In addition MIKA Pharma is developing a broad clinical pipeline of topical products for the treatment of pain and inflammation.
Bernd Seigfried, CEO of MIKA comments: "Giuliani S.p.A is the preferred strategic partner to further develop our international clinical projects. At the same time we already have products in commercial stage, here as well Giuliani S.p.A will help to faster exploit the various market opportunities."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.